When was Clene Nanomedicine founded?

Clene Nanomedicine was founded in 2012 and raised its 1st funding round 7 years after it was founded.

Where is Clene Nanomedicine located?

Clene Nanomedicine is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah.

How many employees does Clene Nanomedicine have?

As of Jun 30, 2026, the latest employee count at Clene Nanomedicine is 72.

Is Clene Nanomedicine a funded company?

Clene Nanomedicine is a funded company, having raised a total of $42.5M across 8 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Mar 07, 2019.

When was the latest funding round of Clene Nanomedicine?

Clene Nanomedicine's latest funding was a $***** Post IPO round on Oct 01, 2024, with participation from 0 investor.

What is the annual revenue of Clene Nanomedicine?

Annual revenue of Clene Nanomedicine is less than $1M as on Dec 31, 2025

Where does Clene Nanomedicine rank among its competitors?

Clene Nanomedicine ranks 127th amongst 1222 active competitors, of which 391 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Clene Nanomedicine?

Clene Nanomedicine's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Clene Nanomedicine - 2026 Company Profile, Funding, Competitors & Financials

Clene Nanomedicine is a public company based in Salt Lake City (United States), founded in 2012. It operates as a Developer of therapeutics for the treatment of neurodegenerative diseases. Clene Nanomedicine has raised $42.5M in funding. The company has 1222 active competitors, including 391 funded and 221 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of therapeutics for the treatment of neurodegenerative diseases. The company focused on revolutionizing the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Their approach centers on developing novel clean-surfaced nanotechnology therapeutics that target cellular energy impairments common in these diseases to restore and protect neuronal health and function.

Website: clene.com
Email ID: *****@CleneNanomedicine.com
Phone Number: +1 **********
Registered Address: Salt Lake City, Utah

Key Metrics

Founded Year

2012

Location

Salt Lake City, United States

Stage

Public

Total Funding

$42.5M in 8 rounds

Latest Funding Round

Post IPO, Oct 01, 2024, $*****

Investors

SymBiosis & 8 more

Ranked

127^th among 1222 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2025

Employee Count

72 as on Jun 30, 2026

Similar Companies

Denali Therapeutics & 926 more

Exit Details

Public

View Clene Nanomedicine's full profile

Clene Nanomedicine is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CLENE INC. CIN: 1822791 , United States, Active	Aug 11, 2020	$0 - $1M (As on Dec 31, 2025)	-	-
CLENE NANOMEDICINE INC CIN: 320446164 , United States, Active	Dec 31, 1999	-	99 (As on Dec 31, 2021)	-

Clene Nanomedicine got listed on Dec 31, 2020.

Click here to take a look at Clene Nanomedicine's IPO in detail

Clene Nanomedicine has raised a total funding of $42.5M over 8 rounds. Its first funding round was on Mar 07, 2019. Clene Nanomedicine has 9 institutional investors.

Here is the list of recent funding rounds of Clene Nanomedicine:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2024	3282139	Post IPO	3389516	9917005	2410559	8823907
Dec 13, 2021	6906034	Grant (prize money)	1325569	4781021	3453109	Maryland
May 25, 2021	2604525	Post IPO	8797897	9276250	7018197	5923450

Access funding benchmarks and valuations. Sign up today!

View details of Clene Nanomedicine's funding rounds and investors

Clene Nanomedicine's employee count trend

Clene Nanomedicine has 72 employees as of Jun 26. Here is Clene Nanomedicine's employee count trend over the years:

Employee count trend for Clene Nanomedicine

Uncover Clene Nanomedicine's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Clene Nanomedicine include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Clene Nanomedicine, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
5th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
6th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	Orbimed, HBM Healthcare Investments & 6 others	69/100
7th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
8th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 10 others	68/100
9th	Neurocrine 1992, San Diego (United States), Acquired	Developer of small molecule therapeutics for endocrine and CNS disorders	$10M	Venrock, BB Biotech & 6 others	68/100
10th	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
127th	Clene Nanomedicine 2012, Salt Lake City (United States), Public	Developer of therapeutics for the treatment of neurodegenerative diseases	$42.5M	SymBiosis, KSV Global & 7 others	54/100